12 Month Price Forecast For EYEG
Distance to EYEG Price Forecasts
EYEG Price Momentum
๐ค Considering EyeGate (EYEG)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 10, 2025 4:36 PM UTC
EYEG Analyst Ratings & Price Targets
Based on our analysis of 2 Wall Street analysts, EYEG has a consensus that is bullish. The median price target is $0.00, with forecasts ranging from $0.00 to $0.00. Currently, there are 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
With EYEG currently trading at $35.23, the median price forecast suggests a -100.0% downside. The most optimistic forecast comes from at HC Wainwright & Co., projecting a -100.0% downside, while at HC Wainwright & Co. provides the most conservative target, suggesting a -100.0% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
EYEG Analyst Consensus
EYEG Price Target Range
Latest EYEG Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for EYEG.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Aug 16, 2021 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $11.00 |
Nov 12, 2020 | HC Wainwright & Co. | Buy | Maintains | $0.00 | |
Jul 21, 2020 | Alliance Global Partners | Buy | Initiates | $0.00 | |
May 19, 2020 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
Nov 15, 2017 | H.C. Wainwright | Buy | Maintains | $0.00 | |
Apr 7, 2016 | Noble Financial | Buy | Initiates | $0.00 |
Stocks Similar to EyeGate Pharmaceuticals Inc
The following stocks are similar to EyeGate based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
EyeGate Pharmaceuticals Inc (EYEG) Financial Data
EyeGate Pharmaceuticals Inc has a market capitalization of $161.21M with a P/E ratio of -19.9x. The company generates $12,059 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of N/A and return on equity of +7.5%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
EyeGate Pharmaceuticals Inc (EYEG) Company Overview
About EyeGate Pharmaceuticals Inc
Invests in investment grade fixed-income securities.
The fund generates returns by investing at least 80% of its net assets in investment grade fixed-income securities from corporate issuers. It capitalizes on interest income and potential capital appreciation from these securities, which may include corporate entities with government ownership interests.
The fund focuses on stable, investment-grade securities, which typically offer lower risk and provide consistent income, making it appealing to conservative investors seeking reliable returns.
EyeGate Pharmaceuticals Inc (EYEG) Latest News & Analysis
Bonds still bouncing along
5 months agoBonds continue to show fluctuations in performance, indicating ongoing volatility in the market. Investors should monitor bond trends closely.
Stable bond performance indicates low volatility, which can influence interest rates and market confidence, impacting equity investments and overall portfolio strategies.
AllianceBernstein Launches 5 New Active ETFs
1 year agoAllianceBernstein has launched five active ETFs, two on the NYSE and three on Nasdaq, following its recent achievement of over $1 billion in active ETF AUM.
AllianceBernstein's launch of five active ETFs signals growth in its market presence and could attract more capital, enhancing competition and investment opportunities in the ETF space.
AllianceBernstein has launched a new ETF suite featuring one Buffered product and four Fixed Income products, expanding its investment offerings.
The launch of new ETFs by AllianceBernstein could attract investor interest, potentially increasing assets under management and impacting overall market dynamics in fixed income.
EyeGate Pharmaceuticals has incorporated Bayon Therapeutics' vision-restoring small molecules into its development pipeline, expanding its product offerings in ophthalmology.
EyeGate's acquisition of Bayon Therapeutics' vision-restoring molecules could enhance its product offerings, potentially boosting future revenue and market position in the ophthalmic sector.
EYEG Stock Price: Why It Substantially Increased
3 years agoEyegate Pharmaceuticals Inc (NASDAQ: EYEG) saw its stock price rise by 22.95% in the last trading session. Further details on the cause were not provided in the excerpt.
A 22.95% stock price surge indicates strong investor interest, potentially driven by positive news or earnings. Such movements can signal volatility and investment opportunities.
Seven Nasdaq-listed penny stocks are suggested for portfolios, offering potential safety while accommodating risk.
Penny stocks listed on Nasdaq may offer higher liquidity and perceived credibility, potentially attracting risk-tolerant investors seeking growth in undervalued securities.
Frequently Asked Questions About EYEG Stock
What is EyeGate Pharmaceuticals Inc's (EYEG) stock forecast for 2025?
Analyst forecasts for EyeGate Pharmaceuticals Inc (EYEG) are not currently available. The stock is trading at $35.23.
Is EYEG stock a good investment in 2025?
According to current analyst ratings, EYEG has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $35.23. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for EYEG stock?
Price predictions from Wall Street analysts for EYEG are not currently available. The stock is trading at $35.23.
What is EyeGate Pharmaceuticals Inc's business model?
The fund generates returns by investing at least 80% of its net assets in investment grade fixed-income securities from corporate issuers. It capitalizes on interest income and potential capital appreciation from these securities, which may include corporate entities with government ownership interests.
What is the highest forecasted price for EYEG EyeGate Pharmaceuticals Inc?
Price targets from Wall Street analysts for EYEG are not currently available. The stock is trading at $35.23.
What is the lowest forecasted price for EYEG EyeGate Pharmaceuticals Inc?
Price targets from Wall Street analysts for EYEG are not currently available. The stock is trading at $35.23.
What is the overall EYEG consensus from analysts for EyeGate Pharmaceuticals Inc?
The overall analyst consensus for EYEG is bullish. Out of 2 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell.
How accurate are EYEG stock price projections?
Stock price projections, including those for EyeGate Pharmaceuticals Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.